HSANZ and a number of other societies have been lobbying for the reimbursement of NGS for myeloproliferative neoplasm. I’m pleased to say that this has been approved for ET/ PV (item 73398) and transplant eligible myelofibrosis (item 73399). Please contact your friendly haematopathology service for details about testing and availability. 

Best wishes
Steven Lane – on behalf HSANZ